Open AccessScreening for immune response against Dengue virus in Vietnamese non‐human primates: implications for vaccine developers
Author(s) -
Lazo Vázquez Laura,
Suzarte Portal Edith,
Castro Velazco Jorge,
Yen Phuong,
Dung Le Trung,
Gil González Lázaro,
Valdés Prado Iris,
Marcos López Ernesto,
Cobas Acosta Karem,
Hien Nguyen Dang,
Guillén Nieto Gerardo,
Hermida Cruz Lisset
Publication year - 2017
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1038/cti.2016.79
Subject(s) - viremia , plaque reduction neutralization test , dengue virus , virology , dengue fever , immunology , dengue vaccine , medicine , immunity , elispot , virus , immune system , peripheral blood mononuclear cell , neutralizing antibody , biology , t cell , in vitro , biochemistry
One of the major problems faced for the development of a vaccine against Dengue virus is the lack of a suitable animal model. Although non‐human primates do not show overt signs of disease, these animals develop viremia after the infection and are the best model to evaluate vaccine candidates against this pathogen. However, for that purpose, the screening of all animals is mandatory to discard those with previous natural immunity. The most common technique used in the screening is the plaque reduction neutralization test (PRNT). However, most recent studies points to the cell‐mediated immunity (CMI) as an important player in the process of controlling Dengue virus (DENV) infections. Here we presented the results from the screening of 55 rhesus monkeys housed in an animal breeding facility at Quang Ninh province, Vietnam. We evaluated the neutralizing antibody response by PRNT and determined the levels of interferon γ (IFNγ)‐secretion after the viral stimulation of monkey‐peripheral blood mononuclear cells, by enzyme‐linked immunosorbent assay (ELISA). We found no correspondence between PRNT and IFNγ‐ELISA. In fact, 19 animals were positive only by IFNγ‐ELISA. Moreover, to study the protective capacity of the CMI detected, three animals with positive response by IFNγ‐ELISA and negative by PRNT were inoculated with an infective preparation of DENV‐3 and, as a result, no viremia was detected during 10 days after the challenge. This fact points to the importance of screening non‐human primates through a CMI assay together with PRNT. This procedure should discard those false‐negative cases which would be protected after the viral challenge in the immunization schedule.